XAMS
BAI
Market cap12mUSD
Mar 12, Last price
0.08EUR
Name
BenevolentAI SA
Chart & performance
P/E
—
P/S
1.32
EPS
—
Div yield, %
—
Shrs. gr., 5y
-5.55%
Rev. gr., 5y
1.44%
Revenues
7m
-30.58%
Net income
-63m
L-61.38%
CFO
-57m
L-25.73%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
BenevolentAI S.A. is a clinical-stage company focused on drug discovery and development, powered by artificial intelligence. Its unique BenevolentAI platform supports an extensive internal pipeline of pharmaceutical programs. The company addresses a broad array of therapeutic areas, including atopic dermatitis, ulcerative colitis, amyotrophic lateral sclerosis, glioblastoma multiforme, inflammatory bowel disease, antiviral conditions, oncology, Parkinson's disease, nonalcoholic steatohepatitis, fibrosis, inflammation, chronic kidney disease, and idiopathic pulmonary fibrosis. Through a collaboration with AstraZeneca, BenevolentAI aims to deepen understanding of complex disease biology and identify novel targets. Founded in 2013, the enterprise is headquartered in London, United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||